EcoDrugPlus

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSOMEG00000006748
Gene Symbol: HTR2A
1 Cross references
214 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSOMEG00000021906
Gene Symbol: HTR2B
3 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 2c-Like

Ensembl ID : ENSOMEG00000018784
Gene Symbol: LOC112156496
3 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSOMEG00000002452
Gene Symbol: HTR3A
3 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSOMEG00000000648
Gene Symbol: HTR3B
2 Cross references
174 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSOMEG00000021442
Gene Symbol: HTR4
3 Cross references
198 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSOMEG00000004444
Gene Symbol: HTR5A
4 Cross references
207 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSOMEG00000020976
Gene Symbol: HTR5A
1 Cross references
5 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSOMEG00000014316
Gene Symbol: HTR7
1 Cross references
196 Possible Orthologues:

60s Ribosomal Protein L10

Ensembl ID : ENSOMEG00000011751
Gene Symbol: LOC112159253
3 Cross references
408 Possible Orthologues:

60s Ribosomal Protein L19

Ensembl ID : ENSOMEG00000021853
Gene Symbol: LOC112146119
3 Cross references
319 Possible Orthologues:

60s Ribosomal Protein L19

Ensembl ID : ENSOMEG00000015008
Gene Symbol: LOC112153824
4 Cross references
317 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).